{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:54Z","timestamp":1786984374678,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.anai.2025.07.025","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:56:18Z","timestamp":1754438178000},"page":"560-569.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lanadelumab\u2019s impact on hereditary angioedema control and quality of life across disease activity subgroups"],"prefix":"10.1016","volume":"135","author":[{"given":"Andrea","family":"Zanichelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Wuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cancian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Kinaciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Recke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. James","family":"Wedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Nova","family":"Estepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmgard","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Juethner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Khutoryansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Martinez-Saguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.anai.2025.07.025_bib0001","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"14","key":"10.1016\/j.anai.2025.07.025_bib0002","first-page":"S292","article-title":"Severity of hereditary angioedema, prevalence, and diagnostic considerations","volume":"24","author":"Bernstein","year":"2018","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.anai.2025.07.025_bib0003","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/jdv.17654","article-title":"Variability of disease activity in patients with hereditary angioedema type 1\/2: longitudinal data from the icatibant Outcome Survey","volume":"35","author":"Maurer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2025.07.025_bib0004","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.jaci.2004.06.047","article-title":"Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond","volume":"114","author":"Agostoni","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.07.025_bib0005","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/all.12209","article-title":"Development, validation, and initial results of the Angioedema Activity Score","volume":"68","author":"Weller","year":"2013","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2025.07.025_bib0006","doi-asserted-by":"crossref","first-page":"246","DOI":"10.18176\/jiaci.0479","article-title":"HAE-AS: a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency","volume":"31","author":"Forjaz","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.07.025_bib0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.anai.2025.07.025_bib0008","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.07.025_bib0009","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.07.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12135","article-title":"Comorbidities in hereditary angioedema\u2014a population-based cohort study","volume":"12","author":"Sundler Bj\u00f6rkman","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anai.2025.07.025_bib0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13223-020-00437-x","article-title":"Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review","volume":"16","author":"Levy","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"34","key":"10.1016\/j.anai.2025.07.025_bib0012","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","article-title":"Inhibition of plasma kallikrein by a highly specific active site blocking antibody","volume":"289","author":"Kenniston","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anai.2025.07.025_bib0013","unstructured":"Food and Drug Administration. TAKHZYRO\u00ae (lanadelumab-flyo) injection, for subcutaneous use. Accessed November 1, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761090s010lbl.pdf"},{"key":"10.1016\/j.anai.2025.07.025_bib0014","unstructured":"European Medicines Agency. Annex I: summary of product characteristics. Accessed November 1, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/takhzyro-epar-product-information_en.pdf"},{"key":"10.1016\/j.anai.2025.07.025_bib0015","unstructured":"Takeda Israel Ltd, TAKHZYRO [Summary of product characteristics]. Accessed November 1, 2024. Available at: https:\/\/mohpublic.z6.web.core.windows.net\/IsraelDrugs\/Rishum01_14_82006724.pdf"},{"key":"10.1016\/j.anai.2025.07.025_bib0016","unstructured":"Takeda Pharma AG. TAKHZYRO\u00ae [information for healthcare professionals]. Accessed November 1, 2024. Available at: https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&lang=EN&authNr=68178&supportMultipleResults=1"},{"key":"10.1016\/j.anai.2025.07.025_bib0017","unstructured":"Takeda Canada Inc. TAKHZYRO\u00ae (lanadelumab injection): product monograph including patient medication information. Accessed November 1, 2024. Available at: https:\/\/pdf.hres.ca\/dpd_pm\/00060484.PDF"},{"issue":"20","key":"10.1016\/j.anai.2025.07.025_bib0018","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.anai.2025.07.025_bib0019","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/all.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.07.025_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaip.2023.09.009","article-title":"Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: results from the phase 3 SPRING Study","volume":"12","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2025.07.025_bib0021","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/cea.13974","article-title":"Effectiveness of lanadelumab for preventing hereditary angioedema attacks: subgroup analyses from the HELP study","volume":"51","author":"Johnston","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.anai.2025.07.025_bib0022","first-page":"2882","article-title":"Sustained effectiveness, tolerability, and safety of long-term prophylaxis with lanadelumab in hereditary angioedema: the prospective, Phase 4, noninterventional EMPOWER real-world study","volume":"45","author":"Bernstein","year":"2025","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.anai.2025.07.025_bib0023","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","article-title":"Development and construct validation of the Angioedema Quality of Life Questionnaire","volume":"67","author":"Weller","year":"2012","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2025.07.025_bib0024","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/all.14144","article-title":"Development of the Angioedema Control Test\u2014a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema","volume":"75","author":"Weller","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2025.07.025_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12955-019-1229-3","article-title":"Angioedema Quality of Life Questionnaire (AE-QoL) - interpretability and sensitivity to change","volume":"17","author":"Kulthanan","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"10.1016\/j.anai.2025.07.025_bib0026","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL) \u2013 assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2025.07.025_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12295","article-title":"Sensitivity to change and minimal clinically important difference of the angioedema control test","volume":"13","author":"Fijen","year":"2023","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.07.025_bib0028","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","article-title":"Validation of the Angioedema Control Test (AECT)\u2014a patient-reported outcome instrument for assessing angioedema control","volume":"8","author":"Weller","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.anai.2025.07.025_bib0029","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1016\/j.jaip.2021.08.019","article-title":"Racial and ethnic disparities in the research and care of hereditary angioedema patients in the United States","volume":"9","author":"Sylvestre","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2025.07.025_bib0030","doi-asserted-by":"crossref","first-page":"AB137","DOI":"10.1016\/j.jaci.2022.12.429","article-title":"Comparison of hereditary angioedema among patients of different races and ethnicities in the United States: data from a real-world study","volume":"151","author":"Anderson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2025.07.025_bib0031","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/cea.14527","article-title":"The Chronic Angioedema Registry (CARE): rationale, methods and implementation","volume":"54","author":"Buttgereit","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2025.07.025_bib0032","unstructured":"Italian Network for Hereditary and Acquired Angioedem (ITACA). Accessed January 29, 2025. Available at: https:\/\/angioedemaitaca.org\/"},{"issue":"9","key":"10.1016\/j.anai.2025.07.025_bib0033","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/MCG.0000000000001744","article-title":"Consider hereditary angioedema in the differential diagnosis for unexplained recurring abdominal pain","volume":"56","author":"Staller","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.anai.2025.07.025_bib0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fmed.2018.00022","article-title":"Hereditary angioedema: the economics of treatment of an orphan disease","volume":"5","author":"Lumry","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"suppl 2","key":"10.1016\/j.anai.2025.07.025_bib0035","doi-asserted-by":"crossref","first-page":"AB89","DOI":"10.1016\/j.jaci.2023.11.297","article-title":"Delayed on-demand treatment of hereditary angioedema attacks: patient perceptions and associated barriers","volume":"153","author":"Christiansen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.07.025_bib0036","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jaip.2024.12.008","article-title":"Real-world effectiveness of lanadelumab in hereditary angioedema: multicountry INTEGRATED observational study","volume":"13","author":"Magerl","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"S113","key":"10.1016\/j.anai.2025.07.025_bib0037","first-page":"93","article-title":"Real-world effectiveness and safety of lanadelumab for hereditary angioedema attack prophylaxis: a 3-year interim analysis of the ENABLE Study","volume":"79","author":"Kinaciyan","year":"2024","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2025.07.025_bib0038","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","article-title":"Adherence, patient preference and dosing frequency: understanding the relationship","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.anai.2025.07.025_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/pai.70072","article-title":"Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER\/ENABLE","volume":"36","author":"Tachdjian","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.07.025_bib0040","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.anai.2024.08.001","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents","volume":"133","author":"Craig","year":"2024","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062500393X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062500393X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T11:57:19Z","timestamp":1766145439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062500393X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S108112062500393X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.07.025","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lanadelumab\u2019s impact on hereditary angioedema control and quality of life across disease activity subgroups","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}